By subscribing to our Newsletter, you will receive curated updates straight to your inbox.
We are pleased to announce the launch of the NANBIOSIS Newsletter, a new communication channel designed to keep our community up to date with the most relevant news and opportunities from our infrastructure.
By subscribing to our Newsletter, you will receive curated updates straight to your inbox every three months, featuring selected content you won’t want to miss. We value your time: we do not spam, and the Newsletter will only be sent to users who actively subscribe.
👉 If you wish to receive future editions, you can subscribe here.
Celebrating 10 Years of NANBIOSIS as an ICTS: Highlights of 2025
To mark the 10th anniversary of NANBIOSIS as a Unique Scientific and Technical Infrastructure (ICTS), our first Newsletter includes a selection of key highlights from 2025:
Featured News
NANBIOSIS Strengthens Internal Collaboration at the 2025 Networking Event in Cáceres
A networking event bringing together Units working in biomaterials, nanomedicine, and biomedical research to foster collaboration. Read the article.
Revalidated as a Unique Scientific and Technical Infrastructure (ICTS)
In November 2025, NANBIOSIS was revalidated as a Spanish ICTS, reaffirming its strategic role in cutting-edge innovation. Read the article.
Danish Students Visit NANBIOSIS Unit 28 (NanoImaging) at IBIMA-BIONAND
International students explored advanced nanoimaging technologies driving innovation in biomedical research. Read the article.
In addition to other interesting scientific highlights. You can read the entire newsletter here.
Stay connected and don’t miss future updates: subscribe to the NANBIOSIS Newsletter and follow the latest developments from our Units, researchers, and infrastructures.
And do not forget, this is the last week for our Open Call! More information here.
Mark your calendar and ready your proposals! The Call is open until the end of January 2026. You can access to it here.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
